Amgen secures a wearable injector deal with Unilife

By Melissa Fassbender

- Last updated on GMT

Image: iStock
Image: iStock

Related tags License Patent

After securing partnerships with AbbVie and Sanofi, Unilife has announced another exclusive agreement for a wearable injector device with Amgen.

The new agreement comes a year after the company’s partnership with Abbvie, and two years after its “unprecedented​” deal with Sanofi.

Unilife CEO Alan Shortfall previously told in-PharmaTechnologist that these deals exemplify pharma’s desire to enhance its biologics offerings through delivery devices.

The most recent deal was announced in an SEC filing on December 31, 2015; however, the companies have until the end of January to finalize their strategic agreement.

According to the filing​, Amgen paid Unilife a non-refundable $15m deposit as consideration for various non-exclusive and exclusive rights and licenses, pursuant to the agreement.

Under the agreement, Unilife grants Amgen “a perpetual, worldwide non-exclusive license under the patents, know-how and technology of the Company​ [Unilife],” for Unilife “to develop, manufacture and supply wearable injector devices existing as of the closing … for use with certain large volume drug products of the Counterparty​ [Amgen].”

Amgen’s license also includes a right to source and/or sublicense the manufacture of up to 20% of their total annual volume needs for such devices. 

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Webinars